tiprankstipranks
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
US Market

Lyell Immunopharma (LYEL) Income Statement

Compare
101 Followers

Lyell Immunopharma Income Statement

Last quarter (Q3 2024), Lyell Immunopharma's total revenue was $34.00K, an increase of 36.00% from the same quarter last year. In Q3, Lyell Immunopharma's net income was $-44.58M. See Lyell Immunopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 130.00K$ 84.68M$ 10.65M$ 7.76M$ 657.00K
Gross Profit
$ 130.00K$ 68.22M$ -3.88M$ 281.00K$ 657.00K
Operating Expenses
$ 247.14M$ 276.50M$ 225.43M$ 219.69M$ 102.75M
Depreciation and Amortization
$ 20.25M$ 16.47M$ 14.54M$ 7.47M$ 4.38M
EBITDA
$ -226.76M$ -166.65M$ -199.94M$ -207.64M$ -100.83M
Operating Income
$ -247.01M$ -183.12M$ -214.78M$ -211.94M$ -102.09M
Other Income/Expenses
$ 12.38M$ 3.84M$ -36.65M$ 7.46M$ -27.29M
Pretax Income
$ -234.63M$ -183.12M$ -250.22M$ -204.47M$ -129.38M
Net Income
$ -234.63M$ -4.75M$ -285.50M$ -198.53M$ -121.26M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.93$ -0.02$ -1.18$ -0.81$ -0.49
Diluted EPS
$ -0.93$ -0.02$ -1.18$ -0.81$ -0.49
Weighted Average Shares Outstanding
250.98M 247.08M 242.74M 246.58M 246.58M
Weighted Average Shares Outstanding (Diluted)
250.98M 247.08M 242.74M 246.58M 246.58M
Currency in USD

Lyell Immunopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis